Search Results

You are looking at 1 - 10 of 10 items for :

  • "gemcitabine" x
  • All content x
Clear All
Free access

He-jun Zhao, Xia Jiang, Li-juan Hu, Lei Yang, Lian-dong Deng, Ya-ping Wang, and Zhi-peng Ren

-stage pancreatic cancer. Gemcitabine, a nucleoside analogue, is used as a first-line treatment for pancreatic adenocarcinomas of all stages ( Valenzuela et al . 2014 ). However, a growing number of patients exhibit the development of resistance to gemcitabine

Free access

Stefania Bulotta, Rosanna Corradino, Marilena Celano, Jessica Maiuolo, Maria D'Agostino, Manuela Oliverio, Antonio Procopio, Sebastiano Filetti, and Diego Russo

Gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells . BMC Cancer 4 63 . ( doi:10.1186/1471-2407-4-63 ). Celano M Schenone S Cosco D Navarra M Puxeddu E Racanicchi L Brullo C Varano E Alcaro S Ferretti E 2008

Free access

Maya Elena Lee, Aisha Aderayo Tepede, Adel Mandl, Lee Scott Weinstein, Jaydira del Rivero, Sunita K Agarwal, and Jenny E Blau

tumors Tivantinib + gemcitabine c-MET (tivantinib), thymidylate synthetase (gemcitabine) Pant et al. (2014) 74 No No 1.4 (partial) 129 Thrombocytopenia, neutropenia, anemia, fatigue, nausea, vomiting, diarrhea, anorexia

Free access

Caterina Mancarella and Katia Scotlandi

, combinations of anti-IGF1R antibodies with cytotoxic agents, such as docetaxel, gemcitabine, erlotinib and doxorubicin, have also been tested ( Macaulay et al . 2013 , Chugh et al . 2015 ) and have yielded durable responses in a few patients with

Free access

H Roger Lijnen and Ilse Scroyen

endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine . European Journal of Pharmacology 498 9 – 18 . ( doi:10.1016/j.ejphar.2004.07.062 ). Carmeliet P Ferreira V Breier G Pollefeyt S Kieckens L Gertsenstein M Fahrig

Free access

Nicola J Smith and Tim R Fenton

agents such as hydroxyurea or gemcitabine also causes ATR/CHK1-dependent upregulation of A3B, at least in breast cancer cell lines ( Kanu et al. 2016 ). High E6/E7 levels might similarly drive A3B upregulation via this as-yet undefined replication

Free access

Marija Trajkovic-Arsic, Evdokia Kalideris, and Jens T Siveke

-blocking antibody ganitumab (AMG 479) in combination with standard of care chemotherapy gemcitabine due to no significant improvement in the overall survival of the patients. IGF and insulin receptors as tyrosine kinases in PDAC One of the potential reasons for

Free access

Douglas Yee

pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF-1R inhibitor . Clinical Cancer Research 19 4282 – 4289 . ( ) 10.1158/1078-0432.CCR-12-1840 Nagle JA Ma Z Byrne MA White MF

Free access

Changgui Shi, Ping Huang, Hui Kang, Bo Hu, Jin Qi, Min Jiang, Hanbing Zhou, Lei Guo, and Lianfu Deng

– 10199 . ( doi:10.1074/jbc.M111.303636 ). Nagano H Tomimaru Y Eguchi H Hama N Wada H Kawamoto K Kobayashi S Mori M Doki Y 2013 MicroRNA-29a induces resistance to gemcitabine through the Wnt/β-catenin signaling pathway in pancreatic

Free access

James W Antoon, William D Meacham, Melyssa R Bratton, Evelyn M Slaughter, Lyndsay V Rhodes, Hasina B Ashe, Thomas E Wiese, Matthew E Burow, and Barbara S Beckman

pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug . Molecular Cancer Therapeutics 8 809 – 820 . doi:10.1158/1535-7163.MCT-08-1096 . Hall JM Korach KS 2003 Stromal cell-derived factor 1, a novel target of estrogen receptor